About this episode

This episode explores how GLP-1 medications are changing consumer behavior and impacting the food and beverage industry.

What happens when millions of people simply stop wanting that second beer? In this episode of Beer In Front, I take a deep dive into the rapidly growing world of GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound—and explore how these drugs are reshaping the food and beverage industry. While most coverage focuses on weight loss, the bigger story may be changing consumer behavior. Research suggests GLP-1 medications don't just reduce appetite, they may also reduce cravings for alcohol, snacks, and other highly rewarding foods by affecting the brain's dopamine reward system. Why GLP-1 users are drinking significantly less alcohol New research showing dramatic reductions in alcohol cravings How wine, beer, and spirits are being affected differently Why bars and restaurants are seeing smaller checks and fewer repeat drink orders The projected $30-$55 billion impact on the food and beverage industry How grocery shopping habits are changing The opportunities for premium alcohol, craft beverages, and non-alcoholic alternatives Why GLP-1 medications could become an important tool in treating alcohol use disorder What breweries, bars, restaurants, and food companies need to…

Explore listener stats, chart rankings, contacts and more on the Beer In Front podcast page.